Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

1281. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma

Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

1282. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer

studied in routine daily practice. Dis Colon Rectum 1997;40:1195-204. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients-French Surgical Association. Cancer 1996;77:1254-62. Indexing Status Subject indexing assigned by NLM MeSH Colorectal Neoplasms /pathology /radionuclide imaging; Cost-Benefit Analysis /methods; Decision Support Techniques; Fluorodeoxyglucose F18 (...) Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer Lejeune C, Bismuth M J, Conroy T, Zanni

2005 NHS Economic Evaluation Database.

1283. Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand

K, Fendrick AM, Ladabaum U. Faecal DNA testing compared to conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 2004; 126:1270-9. Ladabaum U, Song K, Fendrick AM. Colorectal neoplasia screening with virtual colonoscopy: when, at what cost, and with what national impact? Clin Gastroenterol Hepatol 2004;2:554-63. Ladabaum U, Chopra CL, Huang G, et al. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis (...) . Ann Intern Med 2001;135:769-81. Ladabaum U, Scheiman JM, Fendrick AM. Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis. Am J Med 2003;114:546-54. Indexing Status Subject indexing assigned by NLM MeSH Colorectal Neoplasms /diagnosis /economics /prevention & Costs and Cost Analysis; Health Services Needs and Demand /economics; Humans; Mass Screening /economics; Reproducibility of Results; United States; control

2005 NHS Economic Evaluation Database.

1284. Clinical utility and cost-effectiveness of routine preoperative computed tomography scanning in patients with colon cancer

of routine preoperative computed tomography scanning in the management of veterans with colon cancer. Am J Surg 2002;183:499-503. Elmas N, Killi R M, Sever A. Colorectal carcinoma: radiological diagnosis and staging. Eur J Radiol 2002;42:206-23. Indexing Status Subject indexing assigned by NLM MeSH Aged; Colonic Neoplasms /pathology /radiography /surgery; Contrast Media; Cost-Benefit Analysis; Female; Humans; Male; Neoplasm Staging; Patient Care Planning; Preoperative Care; Tomography, X-Ray Computed (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined routine preoperative computed tomography (CT) scanning of the abdomen and pelvis in patients with colon cancer. The patients were scanned at 5-mm intervals from the diaphragm to the pubic symphysis

2005 NHS Economic Evaluation Database.

1285. Family history assessment to detect increased risk for colorectal cancer: conceptual considerations and a preliminary economic analysis

of familial colorectal cancer risk. Am J Gastroenteral 2001;96:2992-3003. Indexing Status Subject indexing assigned by NLM MeSH Adult; Age Factors; Age of Onset; Colorectal Neoplasms /diagnosis /economics /epidemiology /genetics; Cost-Benefit Analysis; Decision Making; Female; Genetic Predisposition to Disease; Health Policy; Humans; Male; Mass Screening /economics; Middle Aged; Pedigree; Prevalence; Research Support, N.I.H., Extramural; Risk Factors AccessionNumber 22006000018 Date bibliographic record (...) ). The probability of developing colorectal cancer at age 40 - 50 was 0.185% (Range: 0.148 to 0.222). The life expectancy benefit for avoidance of colorectal cancer when aged 40 - 50 was 10.35 years (Range: 5 to 12). Methods used to derive estimates of effectiveness The decision model was supported by a number of modelling assumptions. Estimates of effectiveness and key assumptions The model initially assumed that disease progression follows the .polyp age shift/ hypothesis. There is general consensus that most

2005 NHS Economic Evaluation Database.

1286. Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis

Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

1287. Radioimmunotherapy and colorectal cancer

The Netherlands Organization for Health Research and Development (ZonMw), grant number 920-03-220. Bibliographic details Koppe M J, Bleichrodt R P, Oyen W J, Boerman O C. Radioimmunotherapy and colorectal cancer. British Journal of Surgery 2005; 92(3): 264-276 PubMedID DOI Indexing Status Subject indexing assigned by NLM MeSH Antibodies, Monoclonal /therapeutic use; Antigens, Neoplasm /metabolism; Carcinoembryonic Antigen /metabolism; Cell Adhesion Molecules /metabolism; Clinical Trials, Phase I as Topic (...) Radioimmunotherapy and colorectal cancer Radioimmunotherapy and colorectal cancer Radioimmunotherapy and colorectal cancer Koppe M J, Bleichrodt R P, Oyen W J, Boerman O C CRD summary This poorly reported review assessed radioimmunotherapy for colorectal cancer (CRC). The authors concluded that radioimmunotherapy might be an effective adjuvant treatment in CRC, but that more research is needed. The lack of a description of review methods, and no apparent quality assessment of what appears

2005 DARE.

1288. Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clinical trials

Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clinical trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

1289. Laparoscopic versus open right hemicolectomy with curative intent for colon carcinoma

carcinoma. The exclusion criteria applied to the LRH group were: patients with tumours larger than 6 cm in diameter; patients with tumours infiltrating the adjacent organs, as detected by ultrasonography and/or computerised tomography; patients who did not consent to the procedure; patients with intestinal obstruction or perforation; and patients whose oncological staging was Duke's D. Setting The setting was a hospital. The economic study was carried out in China. Dates to which data relate (...) validity of the analysis. The study referred to patients undergoing right hemicolectomy because of colon carcinoma and this was reflected in the authors' conclusions. Implications of the study The study results suggested that LRH for right-sided colon cancer has the same oncological clearance, surgical safety, cost-effectiveness and patient survival as ORH. Further, patients can benefit from quicker postoperative recovery with laparoscopic surgery. The authors noted that the results of their study

2005 NHS Economic Evaluation Database.

1290. CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting

CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

1291. Magnetic resonance colonography versus colonoscopy as a diagnostic investigation for colorectal cancer: a meta-analysis

Magnetic resonance colonography versus colonoscopy as a diagnostic investigation for colorectal cancer: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

1292. Panitumumab for advanced colorectal cancer - horizon scanning review

Panitumumab for advanced colorectal cancer - horizon scanning review Panitumumab for advanced colorectal cancer - horizon scanning review Panitumumab for advanced colorectal cancer - horizon scanning review National Horizon Scanning Centre Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Horizon Scanning Centre. Panitumumab (...) for advanced colorectal cancer - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC) 2005: 6 Authors' objectives This study aims to assess the effectiveness of panitumumab for advanced colorectal cancer. Authors' conclusions Panitumumab (ABX-EGF) is a monoclonal antibody in phase III trials as third- or fourth-line monotherapy in patients with advanced colorectal cancer who have failed previous fluoropyrimidine, irinotecan and/or oxaliplatin chemotherapy regimens. Panitumumab binds

2005 Health Technology Assessment (HTA) Database.

1293. PTK/ZK (Vatalanib) for advanced metastatic colorectal cancer - horizon scanning review

-derived growth factor (PDGF) receptor, and c-KIT. PTK/ZK in combination with oxaliplatin and 5-FU and leucovorin has completed phase III trials as 1st line therapy and 2nd line therapy, (after irinotecan-based chemotherapy), in advanced metastatic colorectal cancer. Results should be available during 2005. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents; Colorectal Neoplasms /drug therapy; Neoplasm Metastasis Language Published English Country (...) PTK/ZK (Vatalanib) for advanced metastatic colorectal cancer - horizon scanning review PTK/ZK (Vatalanib) for advanced metastatic colorectal cancer - horizon scanning review PTK/ZK (Vatalanib) for advanced metastatic colorectal cancer - horizon scanning review National Horizon Scanning Centre Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database

2005 Health Technology Assessment (HTA) Database.

1294. SU11248 for 2nd-line treatment of gastrointestinal stromal tumour (GIST) in patients refractory or intolerant of imatinib mesylate - horizon scanning review

treatment. One phase II trial in 92 patients demonstrated a partial response in 7 patients (8%), and stable disease was achieved in 53 patients (58%). Median time to progression was 34 weeks (range 3 to 94 weeks). Median survival in the overall cohort had not been reached when the data was presented. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents; Enzyme Inhibitors; Gastrointestinal Neoplasms /drug therapy; Protein-Tyrosine Kinases Language Published English (...) SU11248 for 2nd-line treatment of gastrointestinal stromal tumour (GIST) in patients refractory or intolerant of imatinib mesylate - horizon scanning review SU11248 for 2nd-line treatment of gastrointestinal stromal tumour (GIST) in patients refractory or intolerant of imatinib mesylate - horizon scanning review SU11248 for 2nd-line treatment of gastrointestinal stromal tumour (GIST) in patients refractory or intolerant of imatinib mesylate - horizon scanning review National Horizon Scanning

2005 Health Technology Assessment (HTA) Database.

1295. Comparison of laparoscopic and open surgery in colorectal cancer

indications, and specific trials in left colon cancer, to standardise the technique; - an assessment by the colleges of the experience required for performing laparoscopy, of training methods and continuing medical education. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Colorectal Neoplasms /surgery; Laparoscopy Language Published French Country of organisation France English Summary English summary available Address for correspondence 2 avenue du Stade de France, 93218 Saint (...) Comparison of laparoscopic and open surgery in colorectal cancer Comparison of laparoscopic and open surgery in colorectal cancer Comparison of laparoscopic and open surgery in colorectal cancer Poutignat N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Poutignat N. Comparison of laparoscopic and open surgery in colorectal cancer. Paris

2005 Health Technology Assessment (HTA) Database.

1296. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation

and a reassessment of the model is highly recommended when ongoing trials reach completion. Project page URL INAHTA brief and checklist Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents; Costs and Cost Analysis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Stromal Cells Language Published English Country of organisation England Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK (...) Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation Wilson J, Connock M, Song F, Yao G, Fry-Smith

2005 Health Technology Assessment (HTA) Database.

1297. Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: review of Technology Appraisal 33

in combination with 5-fluorouracil and folinic acid as first-line or subsequent therapy. 1.2 Raltitrexed is not recommended for the treatment of patients with advanced colorectal cancer. Its use for this patient group should be confined to appropriately designed clinical studies. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents; Colorectal Neoplasms /drug therapy Language Published English Country of organisation England Address for correspondence MidCity Place, 71 (...) Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: review of Technology Appraisal 33 Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: review of Technology Appraisal 33 Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: review of Technology Appraisal 33 National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology

2005 Health Technology Assessment (HTA) Database.

1298. Cetuximab for the management of advanced colorectal cancer

Cetuximab for the management of advanced colorectal cancer Cetuximab for the management of advanced colorectal cancer Cetuximab for the management of advanced colorectal cancer Pichon Riviere A, Augustovski F, Alcaraz A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Pichon Riviere A, Augustovski F, Alcaraz A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A. Cetuximab for the management of advanced colorectal cancer. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2005 Authors' objectives The aim of this report was to assess the effectiveness of cetuximab for the management of advanced colorectal cancer. Authors' conclusions Without chemotherapy, the average survival in patients with advanced CRC is 6

2005 Health Technology Assessment (HTA) Database.

1299. Relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: part 2, imatinib for gastrointestinal stromal tumors (GIST)

' objectives The aim of this review is to report on the relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy, in particular on imatinib for gastrointestinal stromal tumors (GIST). Project page URL Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents; Gastrointestinal Stromal Tumors /drug therapy; Mouth Neoplasms /therapy; Pyrimidines Language Published English Country of organisation United States Address for correspondence Center (...) Relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: part 2, imatinib for gastrointestinal stromal tumors (GIST) Relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: part 2, imatinib for gastrointestinal stromal tumors (GIST) Relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: part 2, imatinib for gastrointestinal stromal tumors (GIST) Abernethy A P

2005 Health Technology Assessment (HTA) Database.

1300. Genetic testing for susceptibility to hereditary nonpolyposis colorectal cancer

) analysis and/or immunohistochemical staining of the tumor tissue of an affected family member as initial screen(s) before germline mutation testing is performed. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Colorectal Neoplasms, Hereditary Nonpolyposis /genetics /diagnosis /methods Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES (...) Genetic testing for susceptibility to hereditary nonpolyposis colorectal cancer Genetic testing for susceptibility to hereditary nonpolyposis colorectal cancer Genetic testing for susceptibility to hereditary nonpolyposis colorectal cancer Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Genetic testing for susceptibility to hereditary nonpolyposis colorectal

2005 Health Technology Assessment (HTA) Database.